The Scientist

» industry

Most Recent

image: Q&A: From FDA to Industry

Q&A: From FDA to Industry

By | September 27, 2016

Among a subset of US Food and Drug Administration regulators who leave the agency, more than half go to work for pharmaceutical companies, researchers report.

1 Comment

Jazz Pharmaceuticals is set to purchase Celator to acquire an experimental treatment for acute myeloid leukemia.

1 Comment

image: Thermo Fisher to Acquire FEI

Thermo Fisher to Acquire FEI

By | June 1, 2016

In a $4.2 billion deal, the science equipment giant is buying the Hillsboro, Oregon-based electron microscope maker.

0 Comments

image: Do Patents Promote or Stall Innovation?

Do Patents Promote or Stall Innovation?

By | June 1, 2016

A petition recently filed with the Supreme Court triggers renewed debate about the role of patents in the diagnostics sector.

3 Comments

image: E.U. Delays Vote on Roundup

E.U. Delays Vote on Roundup

By | May 24, 2016

Newly published research on the key ingredient in the Monsanto-made weed killer is holding up lawmakers’ decisions on whether to continue to allow its sale in Europe.

4 Comments

The US Department of Agriculture orders Santa Cruz Biotechnology to pay a $3.5 million fine and to cease selling research antibodies.

0 Comments

image: Pfizer Scoops Anacor for $5.3 Billion

Pfizer Scoops Anacor for $5.3 Billion

By | May 17, 2016

The acquisition-hungry pharmaceutical firm is purchasing the California-based eczema gel maker.

0 Comments

image: Lu on Syn Bio

Lu on Syn Bio

By | May 1, 2016

MIT researcher and Scientist to Watch Timothy Lu talks about the value of cross-disciplinary approaches in bringing synthetic biology into the clinic.

0 Comments

image: Timothy Lu: Niche Perfect

Timothy Lu: Niche Perfect

By | May 1, 2016

Associate Professor, Departments of Electrical Engineering & Computer Science and Biological Engineering, MIT. Age: 35

0 Comments

image: Another Gene-Editing IPO

Another Gene-Editing IPO

By | April 12, 2016

Intellia Therapeutics, which seeks to develop CRISPR-based technologies to target rare diseases, is hoping to raise $120 million in an initial public offering.

0 Comments

Popular Now

  1. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  2. How Plants Evolved Different Ways to Make Caffeine
  3. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  4. ESP on Trial
    Foundations ESP on Trial

    In the 1930s, parapsychologist Joseph Banks Rhine aimed to use scientific methods to confirm the existence of extrasensory perception, but faced criticisms of dubious analyses and irreproducible results.

RayBiotech